Axiom Investors’s Kite Pharma, Inc. KITE Stock Holding History

Axiom Investors’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-27,914	Closed	-$2.89M	–	152
2017 Q2	$2.89M	Buy	27,914 +3,219	+13%	+$263K	0.07%	110
2017 Q1	$1.94M	Buy	+24,695	New	+$1.53M	0.05%	124

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Axiom Investors's KITE Position: Q3 2017 in Review

Axiom Investors sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 27,914 shares — an estimated $2.89M sold.

Axiom Investors first reported a position in KITE in Q1 2017 and held it in 2 quarters. The position peaked at $2.89M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Axiom Investors reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Axiom Investors sold 27,914 Kite Pharma, Inc. shares in Q3 2017, an estimated $2.89M.
Axiom Investors first reported a position in Kite Pharma, Inc. in Q1 2017 and held it in 2 quarters.
Axiom Investors's Kite Pharma, Inc. position peaked at $2.89M in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Axiom Investors's 13F filing for Q3 2017, filed 9 Nov 2017.